2006 Drugs Pharmacy Regulations 
Drug Channels
FEBRUARY 21, 2023
On March 14, 2023, Drug Channels Institute will release The 2023 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. drug pricing, reimbursement, and dispensing system. we highlight potential implications of the IRA for the drug channel. Copyright © 2006-2023 Pembroke Consulting, Inc.
Drug Channels
FEBRUARY 22, 2022
On March 15, 2022, Drug Channels Institute will release The 2022 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. drug pricing, reimbursement, and dispensing system. This 2022 edition addresses COVID-19 and its ongoing impact on the pharmacy and PBM industries. d/b/a Drug Channels Institute.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Channels
AUGUST 18, 2020
Hospitals and health systems are building a major presence in the specialty pharmacy industry. As we demonstrate below, nine out of ten large hospitals now operate a specialty pharmacy. accredited specialty pharmacies. Clinical and general financial motivations are driving hospitals’ DIY specialty pharmacy growth.
Drug Channels
OCTOBER 23, 2023
With regulation and policy changes, specifically surrounding the DCSCA, IRA and serialization, the loss of exclusivity wave, adoption of low-WAC products affecting GTN and the rise of alternative distribution models, there has never been a more important time for industry to unite. Drug Channels, or any of its employees.
Common Sense for Drug Policy Blog
JANUARY 5, 2024
Melatonin, the hormone involved in the regulation of our biological clock, is released when we are exposed to daylight. It was only when its use grew further, and more evidence about its addictive potential came to light, that the United States finally passed the 1974 Drug Control Act (Rawson et al. As Crary ( 2013 , p. Chemical 24/7.
Drug Channels
SEPTEMBER 29, 2020
Exclusive Offer for Drug Channels Readers – View the complete agenda and register today – Be sure to use your exclusive promo code USAVE3 to save $300 *. As managing copay programs continues to be significantly more complex, it is imperative to stay on top of current trends, emerging regulations and future legislation.
Agency IQ
SEPTEMBER 15, 2023
FDA’s nonprescription advisors find no efficacy for phenylephrine This week, FDA’s Nonprescription Drugs Advisory Committee (NDAC) voted unanimously that current scientific data do not support the efficacy of oral phenylephrine as a nasal decongestant, aligning with FDA analysis — and re-analysis — of data.
Expert insights. Personalized for you.
97 
Let's personalize your content